Skip to main content

Day: March 24, 2020

Brim hf.: Upplýsingar um breytta framkvæmd aðalfundar

Aðalfundur Brims hf. verður haldinn þriðjudaginn 31. mars kl. 17:00.Þar sem heilbrigðisráðherra hefur ákveðið, í samræmi við tillögu sóttvarnarlæknis, að takmarka samkomur vegna útbreiðslu Covid-19 veirunnar hefur verið lagt bann við því að halda fjölmennan fund. Því hafa forsendur breyst verulega frá því að aðalfundur Brims hf. var auglýstur og ekki lengur tækt að safna hluthöfum saman til fundar á einn stað. Í ljósi þess og ábendingum frá hluthöfum félagsins beinir stjórnin því til hluthafa að mæta ekki á aðalfundinn heldur kjósa fyrirfram skriflega um tillögur fundarins og fela fundarstjóra umboð til að kjósa á fundinum fyrir sína hönd. Gert er ráð fyrir að einungis mæti á fundarstað starfsmenn fundarins, forstjóri og stjórnarformaður. Skrifleg kosningEyðublað fyrir skriflega kosningu og leiðbeiningar er að finna á heimasíðu félagsins:...

Continue reading

Endanleg dagskrá og tillögur fyrir aðalfund Brims hf. 31. mars 2020

Aðalfundur Brims hf. verður haldinn þriðjudaginn 31. mars 2020 og hefst hann klukkan 17:00. Fundurinn fer fram á íslensku.DagskráSkýrsla stjórnar félagsins um starfsemina síðastliðið ár.Endurskoðaður ársreikningur lagður fram til staðfestingar.Tillaga stjórnar um greiðslu arðs.Tillaga stjórnar um starfskjarastefnu.Ákvörðun um þóknun stjórnarmanna.Kosning stjórnar félagsins.Kosning endurskoðenda.Tillaga um að stjórn fái heimild til kaupa á eigin bréfum.Skýrsla stjórnar um kosti og galla tilnefningarnefnda skv. samþykkt síðasta aðalfundarTillaga stjórnar vegna samþykktar á hluthafafundi 12. desember 2019 um að fela stjórn félagsins að leggja fram til samþykktar eða synjunar tillögur sem miða að því að auka möguleika erlendra aðila til óbeinnar fjárfestingar í félaginu.Önnur mál, löglega upp borin.Þar sem heilbrigðisráðherra hefur ákveðið,...

Continue reading

Increased securities lending facilities to primary dealers

Government Debt Management securities lending facilities for primary dealers.According to the Agreements concerning Secondary Market Issuance and Market making in Treasury Securities dated 14 March 2019,  securities lending in series RIKB 21 0805 to each primary dealer will be increased from 1 bn.kr. nominal value up to 2 bn.kr. nominal value. These terms shall take effect on Wednesday 25 March 2020.

Continue reading

Aukin fyrirgreiðsla verðbréfalána

Fyrirgreiðsla Lánamála ríkisins til aðalmiðlara ríkisverðbréfa.Með vísan til samnings í tengslum við útgáfu ríkisverðbréfa og viðskiptavaktar á eftirmarkaði dags. 14. mars 2019 hefur verið ákveðið að auka fyrirgreiðslu í RIKB 21 0805 til hvers aðalmiðlara úr 1 ma.kr. í 2 ma.kr. að nafnverði. Breytingin tekur gildi miðvikudaginn 25. mars.

Continue reading

Resverlogix 臨床候選產品 Apabetalone 在近期刊物中被視為潛在的 COVID-19 治療藥物

阿爾伯塔省卡爾加里, March 25, 2020 (GLOBE NEWSWIRE) — Resverlogix Corp. (「Resverlogix」或「公司」) (TSX:RVX),欣然宣佈 2020 年 3 月 23 日的 bioRxiv 刊物顯示 apabetalone 可抑制專業化蛋白質,或稱為溴結構域和末端外蛋白 (bromodomain and extraterminal domain, BET) 與 SARS-CoV-2 病毒蛋白產生相互作用,因此有潛力限制人類細胞中的病毒繁殖。文章題為:「A SARS-CoV-2-Human Protein-Protein Interaction Map Reveals Drug Targets and Potential Drug-Repurposing (SARS-CoV-2-人類蛋白質-蛋白質相互作用圖揭示藥物標靶和潛在藥物再利用)」,由 Gordon 等人執筆,確定了 BRD2/4 是病毒蛋白 E 的結合伴侶。Apabetalone 被顯示可破壞這種互動。刊物中有一段文字闡述有關 Bromodomain 蛋白的以下內容: SARS-CoV-2 包膜與溴結構域蛋白產生相互作用令人驚訝的是,我們發現跨膜蛋白 E 結合到溴結構域的蛋白 BRD2 和 BRD4,並透過模仿組蛋白結構可潛在破壞 BRD-組蛋白的結合。BRD2 是溴結構域和末端外域家族蛋白 (BET) 的成員,其成員結合乙酰化的組蛋白,藉此調節基因轉錄。組蛋白 2A 的 N 端在蛋白質 E 的大約 15 個殘基的 α-螺旋上具有局部序列相似性,其中一些殘基在跨膜片段中 (Gordon et al., 2020,頁 7)。Donald McCaffrey 主席兼行政總裁 Resverlogix 說:「這項新穎的研究無疑令人非常鼓舞,並且需要對 apabetalone 獨立進行額外測試,這種藥物是我們的試驗性第 3 期臨床候選藥物,涉及超過 4,000...

Continue reading

近期出版物对Resverlogix临床候选药物Apabetalone作为新冠肺炎(COVID-19)潜在治疗药物进行专题报道

阿尔伯塔省卡尔加里, March 25, 2020 (GLOBE NEWSWIRE) — Resverlogix Corp.(以下称“Resverlogix”或“公司”)(TSX:RVX)很高兴地宣布,2020年3月23日发表的一篇bioRxiv文章表示apabetalone可以抑制特定蛋白(含溴结构域和超末端结构域(BET)蛋白)与新冠病毒(SARS-CoV-2)蛋白的相互作用,具有限制病毒在人类细胞中繁殖的潜力。标题为《A SARS-CoV-2-Human Protein-Protein Interaction Map Reveals Drug Targets and Potential Drug-Repurposin》(新冠病毒-人类蛋白与蛋白互作图揭示药物靶标和潜在的老药新用,Gordon等人)的文章将BRD2/4确定为病毒蛋白E的结合配体。Apabetalone已显示出会破坏这种相互作用。文章中的一段陈述了有关溴结构域蛋白的以下内容: 新冠病毒包膜与溴结构域蛋白相互作用出人意料的是,我们发现跨膜蛋白E与含溴结构域的蛋白BRD2和BRD4结合,有可能通过模仿组蛋白来破坏BRD组蛋白结合。BRD2是溴结构域和超末端结构域(BET)族的成员,这一结构域族的成员结合乙酰化的组蛋白来调控基因转录。组蛋白2A的N端在α-螺旋上共同具有大约15个残基的局部序列相似性,其中一些残基位于蛋白E的跨膜片段中(Gordon等人,2020年。第7页)。“这项新研究无疑非常令人鼓舞,显示出对apabetalone进行进一步试验的意义,apabetalone是我们的研究性3期临床候选药物,相关的受试者安全性数据超过4000例。”Resverlogix总裁兼首席执行官Donald McCaffrey表示, “利用表观遗传调控可能是减缓新冠病毒传播和疾病严重程度的有效工具,正如我们昨天宣布的那样,我们希望与临床前和临床研究中测试新冠肺炎药物的任何机构迅速投入合作。”有意进行新冠肺炎相关合作的单位可以通过以下方式联系:Donald...

Continue reading

Business transacted at the annual general meeting

Company Announcement no. 12/2020Today, March 24, 2020, SimCorp A/S held its annual general meeting, at which the following was adopted:Financial year 2019 and 2020         The company’s audited annual report 2019         The amendment of the company’s remuneration policy and the remuneration of the Board of Directors for 2020 and until the next annual general meeting         Distribution of profit according to the adopted annual report 2019. The dividend will be DKK 7.50 per share of DKK 1 and the remainder is transferred to next yearElections and Board related matters         Re-election of Peter Schütze as Chairman and Morten Hübbe as Vice-chairman of the Board of Directors         Re-election of Hervé Couturier, Simon Jeffreys, Adam Warby and Joan A. Binstock as members of the Board of Directors         Re-election of PwC as the company’s...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.